Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia

Acute Lymphoid Leukemia Relapse Clinical Trial

— Anti-CD19-ALL  

Official title:

A Prospective Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05366218
• Other study ID #: 2022-000557-88
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: March 8, 2023
• Est. completion date: March 2027

Study information

• Verified date: July 2023
• Source: University Hospital Tuebingen
• Contact: Peter Lang, Prof.
• Phone: 0049 7071 2984744
• Email: peter.lang[@]med.uni-tuebingen.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of the trial is to evaluate the safety, clinical toxicity and in vivo immunological effects of MOR00208 in pediatric patients with acute lymphoblastic leukemia who showed newly emerging or persistent MRD after a first stem cell transplantation, received stem cell transplantation without having reached a sufficient molecular remission prior to transplant (defined as MRD ≥10E-4) irrespective of MRD after SCT or underwent a second or subsequent stem cell transplantation irrespective of MRD after SCT.

Part I: to determine the recommended dose of MOR00208 in pediatric patients Part II: to evaluate the time until hematological relapse or increase of MRD

Description:

Acute lymphoblastic leukemia is the most common malignancy in children. In patients with > 2nd relapse or in patients who relapse after previous stem cell transplantation (SCT), conventional chemotherapy or even subsequent SCT results only in low probabilities for event free survival (1-year EFS ~30%) with a generally poor prognosis. Major cause of death is a subsequent relapse. To date there is no standard therapy available. The aim of this study is to establish an antibody approach as an additional therapy. Therefore, the safety and efficacy of the anti-CD19-antibody tafasitamab in such pediatric very high-risk patients will be evaluated. Patients will be included in the following stages of disease: newly emerging or persistent minimal residual disease (MRD) after a first SCT; SCT without having reached a sufficient molecular remission prior to transplant (defined as MRD ≥10E-4) irrespective of MRD after SCT; underwent a second or subsequent SCT irrespective of MRD after SCT. Tafasitamab will be used as a relapse prophylaxis as well as a treatment for patients with low detectable low MRD. The treatment is intended to reduce the likelihood of overt relapse after SCT in a collective of patients at highest risk of relapse, thereby improving the long-term survival of these patients. The bi-weekly application of anti-CD19-antibody has already shown promising results in compassionate use settings in pediatric patients. Furthermore, the safety of tafasitamab has already been analyzed in multiple studies in adults and has proven to be well tolerable. As a control group published data for these patient groups will be used with a combined 1-year EFS of 30% in which patients have been treated at the current standard of care.

The study consists of 2 parts:

The first part will evaluate safety along with the maximum tolerated dose of tafasitamab in pediatric patients. This will involve intra- and inter-individual dose escalation using pre-determined dose levels before the dose-finding phase is completed. If dose-limiting drug side effects occur during this dose-finding phase, additional patients will be included in the interindividual dose escalation until the maximum tolerated dose of tafasitamab is defined for the remainder of the study. For this dose-finding phase, a minimum of six and a maximum of 25 patients will be included.

Immediately thereafter, the second study phase begins, in which all patients from the dose-finding phase who have not experienced a dose-limiting toxicity, as well as additional enrolled patients, receive the defined maximum tolerated dose of tafasitamab. In this phase of the study, in addition to the continued recording of drug side effects, the efficacy of tafasitamab will be assessed using defined endpoints. A minimum evaluable number of 18 patients is planned for the assessment of these endpoints; to compensate for possible patient dropout during the study, recruitment of a minimum of 20 patients and a maximum of 39 patients, depending on the course of the dose-finding phase, is planned.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: March 2027
• Est. primary completion date: March 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 18 Years

Eligibility

Inclusion Criteria:

• B-lineage (CD19 positive) ALL (B, pro-B, pre-B or c-ALL)

• Patients must have either

• underwent a first allogeneic stem cell transplantation with newly emerging or persistent MRD load posttransplant or

• have received stem cell transplantation without having reached a sufficient molecular remission prior to transplant (defined as MRD =10E-4) irrespective of MRD after SCT or

• underwent a second or subsequent allogeneic stem cell transplantation irrespective of MRD after SCT

• Females of childbearing potential (FCBP1) must agree

• to utilize two reliable forms of contraception simultaneously or practice complete abstinence from heterosexual contact for at least 3 months before starting study drug, while participating in the study (including dose interruptions), and for at least 3 months after study treatment discontinuation and must agree to regular pregnancy testing during this timeframe

• to abstain from breastfeeding during study participation and 3 months after study drug discontinuation.

• Males must agree

• to use a latex condom during any sexual contact with FCBP while participating in the study and for 3 months following discontinuation from this study, even if he has undergone a successful vasectomy

• to refrain from donating semen or sperm during study participation and for 3 months after discontinuation from this study treatment.

Exclusion Criteria:

• Frank relapse (>5% leukemic blasts)

• Philadelphia chromosome-positive (Ph+) ALL

• Ejection fraction <25% on echocardiography

• Cystatin C-clearance <40ml/min

• Liver function abnormalities with bilirubin >4 mg/dL and elevation of transaminases higher than 400 U/L

• Severe infection (HIV, Chronic active viral hepatitis), tests have to be conducted at screening

• Acute GvHD III-IV or extensive chronic GvHD

• The following immunosuppressive drugs (= 1 week of administration): steroids = 1mg/kg body weight, cytostatics (except intrathecal/intracerebroventricular application for CNS treatment)

• Application of other experimental therapy modalities in the last 4 weeks

• Significant psychiatric disabilities, uncontrolled seizure disorders or severe peripheral neuropathy/ leukoencephalopathy

• Signs of autoimmune disease (i.e. idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia)

• Subjects that do not agree to refrain from donating blood while on study drug

• Concurrent severe or uncontrolled medical disease which by assessment of the treating physician could compromise participation in the study

• Women during pregnancy and lactation

• History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product.

Related Conditions & MeSH terms

• Acute Lymphoid Leukemia Relapse
• ALL, Childhood B-Cell
• Leukemia
• Leukemia, Lymphoid
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Recurrence

Intervention

Biological:
• Tafasitamab
Antibody vaccination

Locations

Country	Name	City	State
Germany	Universitätsmedizin Berlin, Campus Virchow Klinikum	Berlin
Germany	Universitätsklinikum Düsseldorf	Düsseldorf	Nordrhein-Westfalen
Germany	Universitätsklinikum	Essen
Germany	Universitätsklinikum, Klinik für Kinder- und Jugendmedizin	Frankfurt
Germany	Universitätsklinikum Freiburg	Freiburg	Baden-Württemberg
Germany	Zentrum für Geburtshilfe, Kinder- und Jugendmedizin	Hamburg
Germany	Universitätsklinikum Schleswig-Holstein, Campus Kiel	Kiel
Germany	Klinikum Dr. von Haunersches Kinderspital	München	Bayern
Germany	University childrens Hospital	Tübingen	Baden-Württemberg
Germany	Klinik für Kinder- und Jugendmedizin	Ulm	Baden-Württemberg
Germany	Universitäts-Kinderklinik	Würzburg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital Tuebingen

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary endpoint Part I	Determination of maximum tolerated dose of MOR00208 in pediatric patients	49 days
Primary	Primary endpoint Part II	Time until hematological relapse (> 5% leukemic blasts) or increase of MRD = 2 log in bone marrow during an observation time of 545 days accounting for competing risks	545 days
Secondary	Pharmakokinetic of MOR00208	Mean plasma concentrations of MOR00208 will be calculated and displayed graphically	8 days
Secondary	Safety and toxicity of MOR00208 - Part I	Adverse events will be presented in line listings and also in cumulative tabulations	49 days
Secondary	Treatment success	Rate of patients with treatment success defined as survival without newly emerging MRD or increasing MRD = 2 log in bone marrow or peripheral blood or unacceptable toxicity	365 days
Secondary	Overall survival	OS from date of first dose until end of follow up at 545 days will be analyzed using Kaplan-Meier-Methods, presenting corresponding statistical parameters and 95% confidence limits and Kaplan-Meier survival curves. Patients alive at 545 days and patients that could not be followed up until 545 days but were seen alive at the last visit will be censored.	545 days
Secondary	MRD reduction	The amount of patients with reduction of at least 1 log at any time point compared to baseline MRD measurement between SCT and start of study treatment will be calculated and displayed graphically. Rates and 95%-confidence limits are also provided.	545 days
Secondary	B cell numbers	Mean B cell numbers will be calculated and displayed graphically with 95%-confidence limits.	545 days
Secondary	Cytotoxic lysis	Cytotoxic lysis will be calculated and displayed graphically.	545 days
Secondary	Safety and toxicity of MOR00208 - Part II	Adverse events will be presented in line listings and also in cumulative tabulations	545 days